SavedAdd your journal

Journals / Dicle Tıp Dergisi / 2016 / Cilt: 43 - Sayı: 4

ÖZGÜN MAKALE/ORIGINAL ARTICLE

Psoriasis Hastalarında Biyolojik Tedavinin Sistemik İnflamatuvar Belirteçler ve Plateletcrit Üzerine Etkisi

Bengü Çevirgen CEMİL
Hatice ATAŞ
Pages
477–483
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: NLR, PLR and PCT may be used as a marker to evaluate biological agent treatment efficacy on psoriasis vulgaris patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Psoriasis is a chronic inflammatory skin disease characterized by abnormal proliferation of keratinocytes and inflammatory cell infiltration.
📊
Key Findings & Data:Circulating inflammatory markers are increased in patients with psoriasis.
💡
Conclusion & Impact:Conclusion: NLR, PLR and PCT may be used as a marker to evaluate biological agent treatment efficacy on psoriasis vulgaris patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Psoriasis is a chronic inflammatory skin disease characterized by abnormal proliferation of keratinocytes and inflammatory cell infiltration. Circulating inflammatory markers are increased in patients with psoriasis. The objective of this study is to assess neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), RDW to platelet ratio (RPR) and plateletcrit (PCT) as inflammatory markers in patients with psoriasis whom treated with biological agents. Methods: Forty-two patients with psoriasis vulgaris whom treated with biological agents were evaluated retrospectively. Information about demographics, clinics, and complete blood count of the patients before initiation and after 3 months of biological treatment were collected. Results: Erythrocyte sedimantation rate (ESR), C-reactive protein (CRP), neutrophil, platelet, PCT, RDW, NLR, and PLR were significantly reduced in the posttreatment results compared with the pretreatment results (p<0,05). Also, there were no statistically significant difference in terms of MPV, PDW, LMR, and RPR results (p>0,05). Conclusion: NLR, PLR and PCT may be used as a marker to evaluate biological agent treatment efficacy on psoriasis vulgaris patients.

Özet

Amaç: Psoriasis keratinositlerin anormal proliferasyonu ve inflamatuvar hücre infiltrasyonu ile karakterize kronik inflamatuvar bir deri hastalığıdır. İnflamatuvar hücre ve sitokinler hastaların dokuları ile birlikte periferal kanda da tespit edilmektedir. Bugüne kadar psoriasis vulgariste pek çok inflamatuvar belirteç bildirilmiştir. Çalışmamızın amacı psoriasisli hastalarda biyolojik tedavi öncesi ve sonrası nötrofil/lenfosit oranı (NLO), lenfosit/monosit (LMO), platelet/lenfosit oranı (PLO), RDW/platelet (RPO) gibi sistemik inflamatuvar belirteçler ile plateletcrit (PCT)' nin değişimini araştırmaktır. Yöntemler: Biyolojik ajanlar ile tedavi edilmiş 42 psoriasis vulgaris hastası geriye dönük olarak değerlendirilmiştir. Hastaların demografik bilgileri, klinik verileri ve tam kan sayımı biyolojik tedavinin başlangıcından önce ve tedavi sonrası 3. ayda değerlendirilmiştir. Bulgular: Sedimentasyon, C-reaktif protein (CRP), nötrofil, trombosit, PCT, RDW, NLO ve PLO değerleri tedavi sonrası tedavi öncesi döneme göre istatistiksel anlamlı olarak azalmıştır (p 0.05). Sonuç: NLO, PLO ve PCT psoriasis vulgaris hastalarının biyolojik ajan ile tedavi etkinliğinin değerlendirilmesinde bir belirteç olarak kullanılabilirler.

🔖

Cite This Article

CEMİL, B. Ç., ATAŞ, H. (2016). ÖZGÜN MAKALE/ORIGINAL ARTICLE. Dicle Tıp Dergisi, Cilt: 43 - Sayı: 4, 477–483. https://ajindex.com/articles/212429

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;94:302-9
  2. Hatipoğlu H, Erkal S, Türkmen S, ve ark. Enfeksiyon Hastalıklarının Tanısında Laboratuvar Bulguları. JOPP Derg, 2011;3:5-11
  3. Bugada D, Allegri M, Lavand'homme P, et al. Inflammationbased scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients. Biomed Res Int. 2014;2014:142425
  4. Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammationbased prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2012;7:587-94
  5. Yamagishi T, Fujimoto N, Nishi H, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma. Lung Cancer. 2015;90:111-7
  6. Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013;72:104-10
  7. Kim DS, Shin D, Jee H, et al. Red blood cell distribution width is increased in patients with psoriasis vulgaris: A retrospective study on 261 patients. J Dermatol. 2015;42:567-71
  8. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a populationbased study. Arch Dermatol. 2005;141:1537-41
  9. Yamanaka K, Umezawa Y, Yamagiwa A, et al. Biologic therapy improves psoriasis by decreasing the activity of monocytes and neutrophils. J Dermatol. 2014;41:679-85
  10. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013;11:88
  11. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137:19-27
  12. Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169:266-82
  13. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004;150:917-28
  14. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNFalpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005:273-9
  15. Boehncke WH. Perspective: Don't be superficial. Nature. 2012;492:55
  16. İlhan M, İlhan G, Gök AF, et al. Evaluation of neutrophillymphocyte ratio, platelet-lymphocyte ratio and red blood cell distribution width-platelet ratio as early predictor of acute pancreatiti